R 21

Drug Profile

R 21

Alternative Names: Malaria virus-like particle vaccine - MultiMalVax; Plasmodium falciparum circumsporozoite protein/HBsAg subunit vaccine - Multimalvax; R21

Latest Information Update: 18 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Oxford
  • Developer GlaxoSmithKline; University of Oxford
  • Class Antimalarials; Parasitic vaccines; Subunit vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Falciparum malaria

Most Recent Events

  • 22 Apr 2017 Safety and Immunogenicity data from a phase I trial in Malaria presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (CMID-2017)
  • 01 Aug 2016 Phase-I clinical trials in Falciparum malaria (Prevention) in Burkina Faso (IM) (NCT02925403)
  • 01 Aug 2016 Phase-I/II clinical trials in Falciparum malaria (Prevention) in United Kingdom (IM) (NCT02905019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top